Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Incyte < Previous 1 2 3 4 Next > Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents April 20, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences April 18, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report First Quarter Financial Results April 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs) March 27, 2023 From Incyte Via Business Wire Tickers INCY Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets March 23, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC) March 22, 2023 From Incyte Via Business Wire Tickers INCY Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting March 06, 2023 From Incyte Via Business Wire Tickers INCY Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis March 03, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference February 16, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa February 10, 2023 From Incyte Via Business Wire Tickers INCY Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs February 07, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference January 24, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report Fourth Quarter and Year-End 2022 Financial Results January 17, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences December 15, 2022 From Incyte Via Business Wire Tickers INCY Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session December 11, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022 December 10, 2022 From Incyte Via Business Wire Tickers INCY Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia December 02, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences November 17, 2022 From Incyte Via Business Wire Tickers INCY Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting November 07, 2022 From Incyte Via Business Wire Tickers INCY More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting November 03, 2022 From Incyte Via Business Wire Tickers INCY Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs November 01, 2022 From Incyte Via Business Wire Tickers INCY Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine October 19, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Report Third Quarter Financial Results October 11, 2022 From Incyte Via Business Wire Tickers INCY Incyte Names New Member to Its Board of Directors October 04, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody October 03, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 From Incyte Via Business Wire Tickers INCY Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress August 24, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference August 23, 2022 From Incyte Via Business Wire Tickers INCY Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs August 02, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo July 18, 2022 From Incyte Via Business Wire Tickers INCY < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
